Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center